In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Commercial Strategies

Set Alert for Commercial Strategies

A Next-Gen Approach To Health Care Risk And Compliance

Across the health care industry, the increasing numbers of ethics violations, data breaches and reputational challenges reflect the growing magnitude and prevalence of compliance failures.

Commercial Strategies Business Strategies

Spinning Around – One Company's Bid To Diagnostic-ify The Metabolism

Lifespin is working on tools to characterize a patient’s metabolism and provide more detailed information about a disease.

In Vitro Diagnostics Metabolic

Abbott Buys Bigfoot Biomedical – But What Lurks In The Forest?

Abbott and Bigfoot Biomedical have worked as partners for more than half a decade but will now continue as one. Analysts are questioning whether the merger will simply be a tuck-in for Abbott, or enable it to release an insulin pump of their own.

M & A Diabetic Care

After All The Layoffs, Is Biopharma’s Headcount Still Growing?

While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.

Commercial Strategies Business Strategies

Gene Therapy: What To Expect Now And In The Future

The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.

FDA Gene Therapy

HSBC Innovation Expects Settled Life Science Market By End Of 2024

Michael White, the new UK head of life sciences at HSBC Innovation Banking, made the move from California to join the UK group shortly before Silicon Valley Bank in London collapsed in March 2023. He talks to In Vivo about turbulent life science markets and the future life sciences strategy at HSBC.

Commercial Strategies Commercial

PacBio Scores Hat Trick Of Big News To Start August

A jump in earnings, the acquisition of Apton and the launch of the long-awaited Onso sequencing system – all in one week at Pacific Biosciences.

M & A In Vitro Diagnostics

Healthcare Reform: GE HealthCare On ‘Building A Bridge To The Future State’

System interoperability and building trust in AI capabilities are central to the strategic collaboration and organic growth plans at GE HealthCare, according to US and Canada regional president and CEO Catherine Estrampes, who spoke to In Vivo as the company released the findings of a major survey of clinicians and patients on future healthcare system needs.

Artificial Intelligence Growth

Intuitive Surgical Sees Procedure Volume Surge; Drug Competition Threatens Bariatric Business

The robotic surgery giant reported rapid procedure growth across all surgical division except bariatrics, worrying some investors.

Robotic Surgery Sales & Earnings

It’s Time For A Billion-Dollar Women's Health Fund

Jessica Federer, former chief digital officer at Bayer, talks to In Vivo about making the jump into investing and why women’s health is a rich and deep market set for change.

Financing Women's Health

With Strong Anti-Inflammatory Candidate In Hand, Abivax Execs Carve A Path Forward

With a strong late-stage anti-inflammatory molecule in its pipeline, the challenge for Abivax is to garner the funds to take its obefazimod program forward. To that end, the company is continuing to do a major overhaul of personnel and is sharpening its corporate vision.

Growth Strategy

Pressure Mounts On Pharma To Act On Environmental Targets

There are growing demands from government officials, investors and employees for the pharmaceutical industry to reduce emissions and waste, and – most of all – make environmental sustainability a core part of its business.

Commercial Strategies Business Strategies

Minute Insight: Coloplast Adds Icelandic Wound Care Innovator Kerecis For $1.3BN

Coloplast expects Kerecis' rapid growth to justify the high price of the acquisition. The Icelandic company's skin-substitute products are made from minimally processed cod skins.

Minute Insights M & A

Dealmaking Gives Biotechs Needed Financial Relief, But Deal Terms Are Under Pressure

Biotechs are ready to partner or sell assets to raise cash while turmoil continues in the financial markets, but they are doing so at lower valuations, with IRA and FTC concerns putting further pressure on deal terms.

Deals C-Suite Speaks

Boehringer Ingelheim’s Pagnotta On Adalimumab And Interchangeability

As Boehringer Ingelheim launches the first – and so far, only – interchangeable US adalimumab biosimilar, the firm’s biosimilar commercial brand lead Stephen Pagnotta talks about how the interchangeability designation puts the firm in a unique position when it comes to competing with Humira.

Commercial Strategies Biosimilars

What Do They Want? Securing The Big Pharma Deal

Partnering has changed in many ways in the last 18 months. Financial markets have all but closed to start-ups and investors are consolidating asset bases in the expectation of relatively high inflation continuing for the next few years.

Deals Commercial Strategies
See All